Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression.
Liraglutide, a glucagon-like peptide-1 analog, has been proved to reduce body weight and visceral adipose tissue (VAT) in human studies. In this study, we aimed at examining lipogenetic signal changes in VAT after weight-loss with liraglutide in db/db mice. The mice were divided into two groups: liraglutide-treated group (n=14, 8-week-old, fasting glucose. >10 mmol/L, liraglutide 300 μg/kg twice a day for 4 weeks) and control group (n=14, saline). We found body weight gain and food intake were reduced after liraglutide treatment (P<0.05). Compared to the control group, the VAT weights were significantly lower in the treated group (2.32±0.37 g versus 3.20±0.30 g, P<0.01) than that in control group. In VAT, compared with control group, the lipogenetic transcription factors PPARγ and C/EBPα expressions were both reduced with pAMPK and pACC increased 3.5-fold and 2.31-fold respectively, while pAkt and pP38MAPK were reduced 0.38-fold and 0.62-fold respectively (P<0.01). In conclusion, VAT was reduced after weight loss with AMPK activation and Akt suppression with liraglutide treatment, which was associated with reduction of lipogenetic process in VAT.
Department of Endocrinology, Peking University First Hospital, Beijing, People's Republic of China.
Yimin
Y
Shao
Department of Endocrinology, Peking University First Hospital, Beijing, People's Republic of China.
Geheng
G
Yuan
Department of Endocrinology, Peking University First Hospital, Beijing, People's Republic of China.
Junqing
J
Zhang
Department of Endocrinology, Peking University First Hospital, Beijing, People's Republic of China.
Xiaohui
X
Guo
D055372:AMP-Activated Protein Kinases / Q000378:metabolism*; D000818:Animals; D004789:Enzyme Activation / Q000187:drug effects; D007279:Injections, Subcutaneous; D050152:Intra-Abdominal Fat / Q000187:drug effects* / Q000378:metabolism; D008055:Lipids / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D000069450:Liraglutide / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013329:Structure-Activity Relationship
D008055:Lipids; D000069450:Liraglutide; D051057:Proto-Oncogene Proteins c-akt; D055372:AMP-Activated Protein Kinases
AMP-activated protein kinase; lipogenesis; liraglutide; visceral adipose tissue